Kiora enters exclusive agreement with CKD
Kiora Pharmaceuticals has entered into an exclusive license agreement with Chong Kun Dang Pharmaceutical Corporation for intellectual property related to inherited retinal disease, with an effective date of August 20, 2026. This strategic licensing deal is significant for the company's pipeline and potential future commercial activities.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day